Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Cash from Investing Activities (2021 - 2023)

Pasithea Therapeutics (KTTA) has disclosed Cash from Investing Activities for 3 consecutive years, with $54536.0 as the latest value for Q4 2023.

  • Quarterly Cash from Investing Activities rose 102.33% to $54536.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $75199.0 through Dec 2023, up 103.27% year-over-year, with the annual reading at $11000.0 for FY2025, N/A changed from the prior year.
  • Cash from Investing Activities hit $54536.0 in Q4 2023 for Pasithea Therapeutics, up from $50159.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $70121.0 in Q2 2022 to a low of -$2.3 million in Q4 2022.
  • Historically, Cash from Investing Activities has averaged -$248603.7 across 3 years, with a median of -$1951.0 in 2022.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 18007.96% in 2022 and later soared 293.16% in 2023.
  • Year by year, Cash from Investing Activities stood at -$12933.0 in 2021, then tumbled by 18007.96% to -$2.3 million in 2022, then skyrocketed by 102.33% to $54536.0 in 2023.
  • Business Quant data shows Cash from Investing Activities for KTTA at $54536.0 in Q4 2023, $50159.0 in Q3 2023, and $24392.0 in Q2 2023.